|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Inhibition of SUV39H1 leads to transcriptional activation of these genes, especially RIG-I, followed by increased IFNβ and λ<sub>1</sub> production after poly(dA:dT) or RIG-I agonist M8 transfection, Collectively, our findings provide new evidence that the E7 oncoprotein plays a central role in dampening host innate immunity and raise the possibility that targeting the downstream effector SUV39H1 or the RIG-I pathway may be a viable strategy to treat viral and neoplastic disease.<b>IMPORTANCE</b> High-risk HPVs are major viral human carcinogens responsible for approximately 5% of all human cancers.
|
31776268 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We investigated the therapeutic potential of systemic RIG-I activation by short 5'-triphosphate-modified RNA (ppp-RNA) for the treatment of acute myeloid leukemia (AML) in the syngeneic murine C1498 AML tumor model. ppp-RNA treatment significantly reduced tumor burden, delayed disease onset and led to complete remission including immunological memory formation in a substantial proportion of animals.
|
31740809 |
2020 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We conclude that high RIG-I expression associates with poor outcome in OC, which is explainable by local immunosuppression in the tumor bed.
|
31800094 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Phospholipase A and acyltransferase 4 (PLAAT4) is a member of the HREV107 tumor suppressor gene family.
|
31131438 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This study aimed to find out the molecular therapeutic effect of lipo-ATRA on tumour suppressor TIG3 and cell proliferative biomarker PPARγ in B (a) P-induced lung cancer model.
|
31300983 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor cell-intrinsic activation of the RNA receptor retinoic acid-inducible gene-I (RIG-I) can trigger an immunogenic form of programmed tumor cell death, but its impact on antitumor responses remains largely unexplored.
|
30906666 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Consistently, therapeutic targeting of RIG-I with 5'- triphosphorylated RNA in both tumor and nonmalignant host cells potently augmented the efficacy of CTLA-4 checkpoint blockade in several preclinical cancer models.
|
31519811 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
RIG-I-knocked-down HCC cells showed upregulated expression of stem cell marker genes, enhanced secretion of factors suppressing in vitro generation of DCs into the conditioned medium (CM), and induction of a phenotype of tumor-infiltrating DCs (TIDCs) with low levels of DC markers in their tumors in nude mice.
|
31088527 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Importantly, RIG-I activation in breast tumors increased tumor lymphocytes and decreased tumor growth and metastasis.
|
30224377 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Approaches aimed at non-infectious RIG-I activation in cancers are being tested as a treatment option, with the goal of inducing immunogenic tumor cell death, stimulating production of pro-inflammatory cytokines, enhancing tumor neoantigen presentation, and potently increasing cytotoxic activity of tumor infiltrating lymphocytes.
|
29989043 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
While in hepatocellular carcinoma and acute myeloid leukemia, RIG-I acts as a tumor suppressor through either augmenting STAT1 activation by competitively binding STAT1 against its negative regulator SHP1 or inhibiting AKT-mTOR signaling pathway by directly interacting with Src respectively.
|
28593618 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Gene expression profiling revealed a VS-5584-induced upregulation of RARRES3, a class II tumor suppressor gene.
|
29254208 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Upon transfer to breast cancer cells, unshielded RN7SL1 activates the PRR RIG-I to enhance tumor growth, metastasis, and therapy resistance.
|
28709002 |
2017 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
Lay summary: In this study, we identified G9a histone methyltransferase was frequently upregulated in human HCC and contributes to epigenetic silencing of tumor suppressor gene RARRES3 in liver cancer.
|
28532996 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Here, we analyzed the impact of hypoxia on the expression of RIG-I in various human and murine tumor and nonmalignant cell types and further investigated its function in hypoxic murine melanoma.
|
28468914 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Overexpression of TIG3 suppresses tumor growth in HCC both in vitro and in vivo via ERK1/2 inhibition by promoting apoptosis and inhibiting proliferation and migration.
|
26951515 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Consequently, the tumor burden was greatly alleviated in the RIG-I knockdown group in a xenograft model.
|
25721089 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Activation of RIG-I leads to the induction of antiviral cytokines, in particular type I interferon, the inhibition of a T(H)17 response as well as to the suppression of tumor growth.
|
26392348 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We show that RARRES3 downregulation engages metastasis-initiating capabilities by facilitating adhesion of the tumor cells to the lung parenchyma.
|
24867881 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Under basal condition, RIG-I mRNA level and promoter activity were significantly higher in normal cells versus their tumor counterparts.
|
17516545 |
2007 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Analysis of TIG3 mRNA expression in a large set of cDNA pools derived from matched tumor and normal human tissues showed a significant downregulation of TIG3 in 29% of the cDNA samples obtained from ovarian carcinomas.
|
15856468 |
2005 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tazarotene-induced gene 1 (TIG1) and Tazarotene-induced gene 3 (TIG3) are retinoid acid (RA) target genes as well as candidate tumor suppressor genes in human cancers.
|
15455391 |
2005 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The decreases in tumour differentiation and RARRES3 expression were significantly correlated compared to the adjacent normal tissues (test for trend, P<0.0001).
|
12838316 |
2003 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The retinoid-inducible gene I (RIG1), belonging to the family of type II tumor suppressor genes, was isolated from human gastric cancer cells treated with all-trans retinoic acid.
|
12014653 |
2002 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We have identified the tumor suppressor retinoic acid receptor responder 3 (RARRES3) as a B-CLL-related gene.
|
11587209 |
2001 |